The North East of England has a unique offering for bioprocessing and biopharmaceuticals.

The strong industrial heritage, within large-scale chemical and biomanufacturing and biotechnology make it the perfect place for companies to access research, training, and manufacturing excellence for bioprocessing in the UK.

Fujifilm Diosynth

What is the NBioP?

The NBioP is a strategic partnership between The National Horizons Centre, CPI and FUJIFILM Diosynth Biotechnologies.

The NBioP creates a bioprocessing, biomanufacturing and biotechnology and biopharmaceutical hub making the North East a centre of innovation, with expertise in the full life cycle of biopharmaceuticals, from basic and applied bioprocessing research, through to biopharmaceutical scale up and ultimately, the commercial manufacture of life changing medicines.

Fujifilm Diosynth

Basic and applied research

Scale up of bioprocesses

Manufacturing of biopharma


10 year + talent pipeline


Each organisation brings unique expertise to the partnership, with a proven track record of collaboration. The National Horizons Centre, provides the academic and skills aspect, offering industry-specific scientific expertise in basic and applied research, driving innovation, and providing workforce training and development. CPI leverages its existing industry connections, innovation facilities and expertise to reduce the risk, gain investment and accelerate the development of new biopharmaceutical products and their manufacturing processes. FUJIFILM Diosynth Biotechnologies, a global leader in the contract development and manufacture of biologics, brings its global expertise for the development of new tools and technologies for biopharmaceutical manufacturing applications. This complementary approach is truly unique, with a focus not only on industry growth but also on providing the skilled workforce of the future.

Where is the Northern Bio-Accelerator Partnership?

With a high-density cluster of expertise and a well-developed business ecosystem, the North East offers a bioscience community that is second to none in the UK. Access to a mature supply chain and highly-skilled work force with much lower business costs than other areas of the UK, means a start-up company can establish itself in the region for life and develop alongside the same companies that it can collaborate with throughout its business development lifecycle.

NBioP is based at Darlington's Central Park, with easy access to rail, road and air travel, the hub provides a unique location for the biopharmaceutical industry.

Darlington's Central Park is at the very heart of Darlington's life sciences offer, providing a high-quality business environment with readily available networks, support, and skills to succeed.

The Park covers 30 hectares and is the flagship regeneration project in the town, with a focussed approach to attracting biologics and pharmaceutical industries, to encourage job creation and local economic growth.

About National Horizons Centre

Discover - Develop - Deliver.

The National Horizons Centre (NHC) was founded in conversation with, and for the bioindustry, to discover diseases earlier, develop novel treatments, and deliver life changing medicines to those in need, quicker, safer and affordably.

The NHC, is a £22.3m biosciences research, partnerships and training facility.

  • Research: The NHC offers state-of-the-art analytical and digital infrastructure supporting basic and applied research in the biosciences and across disciplinary boundaries, aligned to bioindustry needs.
  • Partnerships: The NHC is founded on the principle of industry partnerships, working together with organisations to accelerate innovation and growth in the biosciences sector.
  • Training and Education: The NHC's world-class facilities and resources support continued professional development, as well as apprenticeships and a range of taught undergraduate and postgraduate programmes in biosciences.

The NHC has core strengths in:

  • Disease-specific research, to understand the underlying biology of diseases, discovering them earlier in patients, and developing novel therapeutic treatments.
  • Biomanufacturing and biotechnology to develop new approaches to and optimise biotherapeutics, delivering treatments to patients faster, safer and affordably.
  • Digital Analytics and Machine Learning using bioinformatics, image analysis, modelling, virtual and artificial reality, to support the discovery, development and delivery of life changing medicines.

National Horizons Centre | Teesside University

About CPI

CPI works with partners to translate inventions into products and processes that enhance health and wellbeing, protect and improve our environment and increase industrial productivity. As part of the High Value Manufacturing Catapult we support partners across diverse markets, such as pharmaceuticals, speciality chemicals and food and drink, through programmes that have the potential to revolutionise their businesses.

  • Industry Relevant Expertise and Assets: CPI delivers product development, proof of concept and scale up services to help bring novel products and processes to market quickly and cost effectively.
  • Knowledge of Innovation Processes: CPI provides business services and consultancy to reduce risk and speed up time to market.
  • Expertise in Securing Funding for Partners and Clients: TCPI enables the right partnerships, connections and funding routes, at the right time.

CPI has core strengths in:

  • Development, optimisation and scale up of manufacturing processes, enabling cost effective and rapid scale up of promising new medicines.
  • Specialised scaled-down, high-throughput systems to accelerate the development and optimisation of bioprocesses, maximising yield, purity and quality.
  • State-of-the-art facilities enabling development of wider biological products and processes at lab and pilot scale; including cell culture, fermentation, down stream processing and final product formulation and cryopreservation.
  • Technical consultancy and business support services, helping companies understand their routes to market.

About FUJIFILM Diosynth Biotechnologies

FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark.

FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems.

The company offers a comprehensive list of services from cell line development using its proprietary pAVEwayTM microbial and ApolloTMX cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing.

FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation.